A Phase II Trial of Irinotecan and AZD2171 in Patients With Metastatic Colorectal Cancer After Progression on First-Line Oxaliplatin, Fluoropyrimidine, and Bevacizumab
- To determine the proportion of patients who are free from progression at 12 weeks from
the start of second-line therapy.
- To determine objective response rate.
- To determine overall survival.
- To further define the dosing and safety profile of irinotecan hydrochloride and
OUTLINE: This is a multicenter study.
Patients receive irinotecan hydrochloride IV over 90 minutes on days 1 and 8 and oral
cediranib once daily on days 1-21. Treatment repeats every 21 days for at least 2 courses in
the absence of disease progression or unacceptable toxicity.
After completion of study therapy, patients are followed up every 3 months for up to 2 years
from study entry.
Masking: Open Label, Primary Purpose: Treatment
The proportion of patients who are progression-free at 12 weeks from the start of second-line therapy
Bert H. O'Neil, MD
UNC Lineberger Comprehensive Cancer Center
United States: Federal Government
|CCOP - Missouri Valley Cancer Consortium||Omaha, Nebraska 68131|
|Memorial Hospital of South Bend||South Bend, Indiana 46601|
|CCOP - Northern Indiana CR Consortium||South Bend, Indiana 46601|
|Saint Joseph Regional Medical Center||South Bend, Indiana 46617|
|Holden Comprehensive Cancer Center at University of Iowa||Iowa City, Iowa 52242-1002|
|Ellis Fischel Cancer Center at University of Missouri - Columbia||Columbia, Missouri 65203|
|Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill||Chapel Hill, North Carolina 27599-7570|
|Wake Forest University Comprehensive Cancer Center||Winston-Salem, North Carolina 27157-1096|
|CCOP - Hematology-Oncology Associates of Central New York||East Syracuse, New York 13057|
|Hematology Oncology Associates of the Quad Cities||Bettendorf, Iowa 52722|
|Wayne Memorial Hospital, Incorporated||Goldsboro, North Carolina 27534|
|Elkhart General Hospital||Elkhart, Indiana 46515|
|Howard Community Hospital||Kokomo, Indiana 46904|
|South Bend Clinic||South Bend, Indiana 46617|
|Lakeland Regional Cancer Care Center - St. Joseph||St. Joseph, Michigan 49085|
|Fort Wayne Medical Oncology and Hematology||Fort Wayne, Indiana 46815|
|Center for Cancer Therapy at LaPorte Hospital and Health Services||La Porte, Indiana 46350|
|Immanuel Medical Center||Omaha, Nebraska 68122|
|Creighton University Medical Center||Omaha, Nebraska 68131-2197|
|Iredell Memorial Hospital||Statesville, North Carolina 28677|
|Cancer Resource Center - Lincoln||Lincoln, Nebraska 68510|
|Evanston Hospital||Evanston, Illinois 60201-1781|
|Elkhart Clinic, LLC||Elkhart, Indiana 46514-2098|
|Michiana Hematology-Oncology, PC - South Bend||Mishawaka, Indiana 46545-1470|
|Lakeside Cancer Specialists, PLLC||Saint Joseph, Michigan 49085|
|Alegant Health Cancer Center at Bergan Mercy Medical Center||Omaha, Nebraska 68124|
|Rex Cancer Center at Rex Hospital||Raleigh, North Carolina 27607|
|Kinston Medical Specialists||Kinston, North Carolina 28501|
|Lakes Region General Hospital||Laconia, New Hampshire 03246|
|New Hampshire Oncology - Hematology, PA at Payson Center for Cancer Care||Concord, New Hampshire 03301|
|New Hampshire Oncology - Hematology, PA - Hooksett||Hooksett, New Hampshire 03106|